Development of the mouse blastocyst after actinomycin D treatment
Related Experiment Videos
Abstract:
Mouse blastocysts were incubated in vitro with actinomycin D in concentrations of 10-1 to 10-5 mug/ml. After transfer to recipient animals, there was a moderate but significant decrease in implantations at 10-minus 1 to 10-minus 3 and 10-minus 5. There was a severe inhibition of subsequent development at concentrations of 10-minus 1 and 10-minus 2. One of 49 fetuses which developed after actinomycin D treatment had a major malformation; there was one major and one minor abnormality among 95 control fetuses. It is suggested that most of the RNA or protein required to effect implantation is synthesized or coded for prior to the blastocyst state. The moderate but significant decrease in implantations found after actinomycin D treatment at this stage may reflect the ability of the drug to reduce cell adhesiveness. This study confirms the impression that the preimplantation embryo is relatively impervious to teratogenic agents, even one as potent as actinomycin D.
Insights
Actinomycin D treatment moderately decreased mouse blastocyst implantation and severely inhibited development. The preimplantation embryo appears resistant to this potent teratogenic agent, suggesting key RNA/protein synthesis occurs earlier.
Area of Science:
- Developmental Biology
- Reproductive Toxicology
Background:
- The preimplantation embryo's developmental trajectory is critical for successful pregnancy.
- Understanding the impact of teratogenic agents on early embryonic development is crucial for reproductive health.
Purpose of the Study:
- To investigate the effects of actinomycin D, a potent RNA synthesis inhibitor, on mouse blastocyst implantation and subsequent development.
- To assess the sensitivity of the preimplantation embryo to teratogenic insult.
Main Methods:
- Mouse blastocysts were exposed in vitro to varying concentrations of actinomycin D (10⁻¹ to 10⁻⁵ μg/ml).
- Treated blastocysts were transferred to recipient mice to evaluate implantation rates and fetal development.
- Malformation rates in treated and control groups were compared.
Main Results:
- Actinomycin D caused a dose-dependent decrease in implantation rates.
- Severe inhibition of post-implantation development was observed at higher drug concentrations (10⁻¹ and 10⁻² μg/ml).
- The incidence of major malformations was low in both treated and control groups.
Conclusions:
- The preimplantation embryo requires minimal de novo RNA or protein synthesis for implantation.
- Actinomycin D's effect on implantation may be linked to reduced cell adhesiveness.
- The study reinforces the notion that preimplantation embryos exhibit relative resistance to potent teratogenic agents.